Antibodies have been developed that target oxidized lipids, eg, 4E6 antibody and EO6 antibody. These antibodies are directed against oxidized epitopes on the ApoB-100 protein on LDL or against oxidized phospholipids. Some commercial reference laboratories are marketing panels that include multiple markers for cardiovascular risk, including oxidized LDL. For example, one commercial reference lab markets a "triple marker test" that measures HDL-C, oxidized LDL, and hs-CRP.
Some have argued that oxidized LDL measurements give the most accurate snapshot of coronary artery disease (CAD) risk. A 2006 study of 921 subjects, including 490 CAD patients and 431 healthy individuals in the control group, compared the relative ability of oxidized LDL versus LDL-C in identifying patients with CAD. Oxidized LDL showed a six-fold ability over LDL-cholesterol in predicting disease. If the oxidized LDL/HDL-C ratio is measured, the ability to predict risk is further increased.
